Clinical (longitudinal) · PMID 33056965
The influence of long-term retinal protective therapy on glaucoma progression — VialBase Research
Supports the glaucoma-neuroprotection use case with longitudinal human data; cited in the clinical-evidence table.
Last updated · 2020 · Strakhov VV et al. · Vestn Oftalmol
Key findings
- Evaluated long-term retinal-protective (bioregulator) therapy in patients with glaucoma over an extended follow-up
- Associated with slower structural progression of glaucomatous change
- Among the deepest human datasets in the Retinalamin/retinal-bioregulator literature
Long-term retinal-protective therapy and glaucoma progression (PMID: 33056965)
Summary
A longitudinal clinical study found that long-term retinal-protective (bioregulator) therapy was associated with slower structural glaucoma progression, adding follow-up evidence to the glaucoma-neuroprotection rationale.
Relevance
The glaucoma track is Retinalamin‘s deepest human evidence base, and this longitudinal analysis is among its strongest entries. Russian clinical practice; no placebo-controlled Western RCT.
See Also
- Parent compound: Retinalamin